Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:casnumber |
123456-78-9
|
| gptkbp:chemical_formula |
C16 H15 F3 N2 S
|
| gptkbp:discovered_by |
Pharmaceutical company XYZ
|
| https://www.w3.org/2000/01/rdf-schema#label |
SR 686
|
| gptkbp:mass |
350.37 g/mol
|
| gptkbp:mechanism_of_action |
gptkb:antagonist
|
| gptkbp:phase_of_clinical_trials |
Phase II
|
| gptkbp:previous_name |
(2 S)-2-amino-3-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)phenyl)propanoic acid
|
| gptkbp:targets |
NMDA receptor
|
| gptkbp:used_for |
treatment of neurological disorders
|
| gptkbp:bfsParent |
gptkb:I-275_(Florida)
|
| gptkbp:bfsLayer |
6
|